Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTBH0VX)

• DTT Name: Histone deacetylase (HDAC) DTT Info
• Gene Name: HDAC

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[1]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[2]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[3]

26 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[4]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[7]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[3]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[9]
DAC-060	DMACTBM	Keratosis	ED56	Phase 2	[10]
JNJ-26481585	DMKIE9C	Advanced stage follicular lymphoma	2A80	Phase 2	[11]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[12]
Remetinostat	DMJIB89	Basal cell carcinoma	2C32	Phase 2	[3]
Rocilinostat	DMSTH01	Multiple myeloma	2A83	Phase 2	[13]
SHAPE	DMIQB13	Cutaneous T-cell lymphoma	2B01	Phase 2	[14]
CUDC-907	DMHIQDC	Acute myelogenous leukaemia	2A41	Phase 1/2	[3]
EDO-S101	DMI71FN	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Tinostamustine	DMA4DMQ	Multiple myeloma	2A83	Phase 1/2	[15]
Tractinostat	DM8D2LC	Lymphoma	2A80-2A86	Phase 1/2	[3]
CG-200745	DM3U2VY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
CT-200	DMW16VR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
CXD-101	DMRD2B0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
GSK311739	DM70DYV	Rhinovirus infection	CA07	Phase 1	[19]
GSK3117391	DMQZSXD	Rheumatoid arthritis	FA20	Phase 1	[20]
OBP-801	DMPLV9G	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
OKI 179	DMSJWTE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
VTR-297	DM9W0B6	Hematologic tumour	2B33.Y	Phase 1	[22]

12 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ampicidin analog 1	DM2V31C	N. A.	N. A.	Patented	[23]
Ampicidin analog 2	DMZH8S9	N. A.	N. A.	Patented	[23]
Aniline derivative 1	DMDSUGF	N. A.	N. A.	Patented	[24]
Indole-based analog 11	DMVRX7S	N. A.	N. A.	Patented	[24]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[24]
PMID27376512-Compound-PG-11047	DM5K4YF	N. A.	N. A.	Patented	[25]
PMID27376512-Compound-PG-11048	DM3U7RN	N. A.	N. A.	Patented	[25]
PMID28092474-Compound-32	DMC4TQL	N. A.	N. A.	Patented	[26]
PMID28092474-Compound-33	DMRE6GP	N. A.	N. A.	Patented	[26]
PMID28092474-Compound-34	DM6JRCW	N. A.	N. A.	Patented	[26]
PMID29671355-Compound-53	DMCRWV3	N. A.	N. A.	Patented	[27]
PMID29671355-Compound-69	DMU61XP	N. A.	N. A.	Patented	[27]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CS-00028	DMB4FWX	Solid tumour/cancer	2A00-2F9Z	Preclinical	[28]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MKC-1313	DMAITRL	Solid tumour/cancer	2A00-2F9Z	Terminated	[29]

93 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	DM5LSY9	Discovery agent	N.A.	Investigative	[30]
2,2-bis(3-fluorophenyl)-N-hydroxyacetamide	DMTODR2	Discovery agent	N.A.	Investigative	[31]
2,2-bis(4-chlorophenyl)-N-hydroxyacetamide	DM2RKD6	Discovery agent	N.A.	Investigative	[31]
2,2-bis(4-fluorophenyl)-N-hydroxyacetamide	DM5PWQM	Discovery agent	N.A.	Investigative	[31]
2-(methylsulfonylthio)ethyl 2-propylpentanoate	DMM52D3	Discovery agent	N.A.	Investigative	[32]
4-Benzoylamino-N-hydroxy-benzamide	DMYBPFS	Discovery agent	N.A.	Investigative	[33]
4-Butyrylamino-N-hydroxy-benzamide	DMRY6B4	Discovery agent	N.A.	Investigative	[34]
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	DM5AVG3	Discovery agent	N.A.	Investigative	[35]
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	DM0M8G5	Discovery agent	N.A.	Investigative	[36]
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	DMULOHZ	Discovery agent	N.A.	Investigative	[35]
4-Phenylbutyrohydroxamic acid	DMCZKN7	Discovery agent	N.A.	Investigative	[37]
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	DM6CRVS	Discovery agent	N.A.	Investigative	[38]
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	DM7KQXL	Discovery agent	N.A.	Investigative	[32]
5-Mercapto-pentanoic acid phenylamide	DMET3OJ	Discovery agent	N.A.	Investigative	[36]
6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	DM9LKXD	Discovery agent	N.A.	Investigative	[36]
6-benzenesulfinylhexanoic acid hydroxamide	DM2I95Z	Discovery agent	N.A.	Investigative	[39]
6-benzenesulfonylhexanoic acid hydroxamide	DMY9IK8	Discovery agent	N.A.	Investigative	[39]
6-Mercapto-hexanoic acid phenylamide	DMD2FW9	Discovery agent	N.A.	Investigative	[36]
6-Phenoxy-hexane-1-thiol	DMVYIN2	Discovery agent	N.A.	Investigative	[36]
6-phenylsulfanylhexanoic acid hydroxamide	DM3OLM6	Discovery agent	N.A.	Investigative	[39]
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	DMLCGSY	Discovery agent	N.A.	Investigative	[30]
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	DM28GZ7	Discovery agent	N.A.	Investigative	[40]
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	DMY027P	Discovery agent	N.A.	Investigative	[30]
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	DM4VQN8	Discovery agent	N.A.	Investigative	[30]
7-Mercapto-heptanoic acid benzothiazol-2-ylamide	DMPYTHV	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid biphenyl-3-ylamide	DMEQKPO	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid biphenyl-4-ylamide	DMJMOUK	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid phenylamide	DM4912P	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid pyridin-3-ylamide	DMQ9PLA	Discovery agent	N.A.	Investigative	[36]
7-Mercapto-heptanoic acid quinolin-3-ylamide	DMTAGJ1	Discovery agent	N.A.	Investigative	[36]
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	DM23XGW	Discovery agent	N.A.	Investigative	[30]
8-Mercapto-octanoic acid phenylamide	DMD3FWU	Discovery agent	N.A.	Investigative	[36]
8-Oxo-8-phenyl-octanoic acid	DMXDQ25	Discovery agent	N.A.	Investigative	[35]
8-Oxo-8-phenyl-octanoic acid hydroxyamide	DMWM1UL	Discovery agent	N.A.	Investigative	[40]
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	DMVBCID	Discovery agent	N.A.	Investigative	[40]
9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	DMIY3D6	Discovery agent	N.A.	Investigative	[40]
Apicidin	DM83WVF	Solid tumour/cancer	2A00-2F9Z	Investigative	[41]
Azelaic bishydroxamic acid	DMKSQY1	Discovery agent	N.A.	Investigative	[42]
CG-1521	DMN3YEQ	Solid tumour/cancer	2A00-2F9Z	Investigative	[42]
CHAP1	DMBZ0QY	Solid tumour/cancer	2A00-2F9Z	Investigative	[41]
CHAP31	DMOXRID	Solid tumour/cancer	2A00-2F9Z	Investigative	[41]
Cyclostellettamine derivative	DMFTDPQ	Discovery agent	N.A.	Investigative	[43]
N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide	DM5R3ZG	Discovery agent	N.A.	Investigative	[44]
N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide	DMXA9MR	Discovery agent	N.A.	Investigative	[44]
N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide	DMOL79W	Discovery agent	N.A.	Investigative	[44]
N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide	DMTBAPH	Discovery agent	N.A.	Investigative	[44]
N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	DMFYG79	Discovery agent	N.A.	Investigative	[45]
N-(2-aminophenyl)-4-methoxybenzamide	DMTKWUM	Discovery agent	N.A.	Investigative	[46]
N-(2-aminophenyl)nicotinamide	DMRDQ1B	Discovery agent	N.A.	Investigative	[45]
N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	DMDM50P	Discovery agent	N.A.	Investigative	[44]
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	DM0GOPV	Discovery agent	N.A.	Investigative	[47]
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	DMJLFOQ	Discovery agent	N.A.	Investigative	[47]
N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide	DMEP2VM	Discovery agent	N.A.	Investigative	[44]
N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide	DM1L3FM	Discovery agent	N.A.	Investigative	[44]
N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	DMC5G6Y	Discovery agent	N.A.	Investigative	[44]
N-(4-aminobiphenyl-3-yl)nicotinamide	DMXVZIY	Discovery agent	N.A.	Investigative	[45]
N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	DMKN8U6	Discovery agent	N.A.	Investigative	[44]
N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide	DMUHKYW	Discovery agent	N.A.	Investigative	[48]
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	DMSUW7M	Discovery agent	N.A.	Investigative	[35]
N-(5-Hydroxycarbamoyl-pentyl)-benzamide	DMZSGPB	Discovery agent	N.A.	Investigative	[48]
N-(6-Hydroxycarbamoyl-hexyl)-benzamide	DMIZVMT	Discovery agent	N.A.	Investigative	[35]
N-(6-Mercapto-hexyl)-benzamide	DM01Y37	Discovery agent	N.A.	Investigative	[36]
N-hydroxy-2,2-diphenylacetamide	DMX3KRQ	Discovery agent	N.A.	Investigative	[31]
N-hydroxy-2,2-diphenylpropanamide	DM7I2TD	Discovery agent	N.A.	Investigative	[31]
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	DMCN91A	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	DMVK2Y3	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	DMHEQ41	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	DMUOCQB	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	DMVEOBY	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	DMISRMT	Discovery agent	N.A.	Investigative	[33]
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	DMGTNQY	Discovery agent	N.A.	Investigative	[34]
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	DMDUOH4	Discovery agent	N.A.	Investigative	[34]
N-Hydroxy-4-phenylacetylamino-benzamide	DMCRU17	Discovery agent	N.A.	Investigative	[33]
N-hydroxy-9,10-dihydroanthracene-9-carboxamide	DMID3BF	Discovery agent	N.A.	Investigative	[31]
N-hydroxy-9H-xanthene-9-carboxamide	DM0DRHP	Discovery agent	N.A.	Investigative	[31]
N-Hydroxy-N'-(2-methylphenyl)octanediamide	DM865Y2	Discovery agent	N.A.	Investigative	[44]
N-Hydroxy-N'-(3-methylphenyl)octanediamide	DMYRC2M	Discovery agent	N.A.	Investigative	[44]
N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	DMELB07	Discovery agent	N.A.	Investigative	[44]
N-Hydroxy-N'-(4-methylphenyl)octanediamide	DM3DPZ8	Discovery agent	N.A.	Investigative	[44]
N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	DMZA8NC	Discovery agent	N.A.	Investigative	[49]
Octanedioic acid bis-hydroxyamide	DMJNQ9K	Discovery agent	N.A.	Investigative	[37]
Octanedioic acid hydroxyamide pyridin-2-ylamide	DMHNWS1	Discovery agent	N.A.	Investigative	[35]
Octanedioic acid hydroxyamide pyridin-4-ylamide	DM945RK	Discovery agent	N.A.	Investigative	[35]
PSAMMAPLIN A	DM6T0IQ	Discovery agent	N.A.	Investigative	[40]
ST-2986	DMNERM6	Discovery agent	N.A.	Investigative	[50]
ST-2987	DMWXTM8	Solid tumour/cancer	2A00-2F9Z	Investigative	[50]
ST-3050	DM19K2D	Discovery agent	N.A.	Investigative	[50]
ST-5732	DM9FYPM	Discovery agent	N.A.	Investigative	[51]
Suberic bishydroxamic acid	DM235XH	Discovery agent	N.A.	Investigative	[42]
Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	DMBOKSF	Discovery agent	N.A.	Investigative	[36]
Trapoxin	DMXZAH6	Discovery agent	N.A.	Investigative	[52]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[53]
Trifluoromethylketone	DMEPFAB	Discovery agent	N.A.	Investigative	[42]

References

• [1] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [2] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [5] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [9] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [10] Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] National Cancer Institute Drug Dictionary (drug id 698408).
• [14] Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
• [15] The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018 Feb 27;11(1):32.
• [16] Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379.
• [17] Clinical pipeline report, company report or official report of Celleron.
• [18] Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7.
• [19] Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014.
• [20] The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42.
• [21] Clinical pipeline report, company report or official report of OnKure Therapeutics.
• [22] Clinical pipeline report, company report or official report of Vanda Pharmaceuticals.
• [23] Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30.
• [24] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [25] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
• [26] Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
• [27] HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
• [28] US patent application no. 2009,0162,329, Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure.
• [29] ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005.
• [30] Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.
• [31] Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
• [32] New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7.
• [33] Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5.
• [34] Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74.
• [35] Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7.
• [36] Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
• [37] Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
• [38] Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.
• [39] Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.
• [40] Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
• [41] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [42] Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
• [43] Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.
• [44] Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
• [45] Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
• [46] Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
• [47] Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.
• [48] Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79.
• [49] Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
• [50] N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
• [51] Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3.
• [52] Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6.
• [53] Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15.